REZOLVE (ANZGOG-1101): A Phase 2 Trial of Intraperitoneal Bevacizumab to Treat Symptomatic Ascites in Patients With Chemotherapy-Resistant, Epithelial Ovarian Cancer

February 25, 2021 5:00 pm

For cancer patients, including those with recurrent ovarian cancer, an important cause of morbidity is malignant ascites. Researchers here evaluated the activity of intraperitoneal injections of low-dose bevacizumab in delaying re-accumulation of malignant ascites in women with chemotherapy-resistant epithelial ovarian … Read more